OBJECTIVE: Central pain augmentation resulting from enhanced excitatory and/or decreased inhibitory neurotransmission is a proposed mechanism underlying the pathophysiology of functional pain syndromes such as fibromyalgia (FM). Multiple functional magnetic resonance imaging studies implicate the insula as a region of heightened neuronal activity in this condition. Since glutamate (Glu) is a major cortical excitatory neurotransmitter that functions in pain neurotransmission, we undertook this study to test our hypothesis that increased levels of insular Glu would be present in FM patients and that the concentration of this molecule would be correlated with pain report. METHODS: Nineteen FM patients and 14 age- and sex-matched pain-free controls underwent pressure pain testing and a proton magnetic resonance spectroscopy session in which the right anterior insula and right posterior insula were examined at rest. RESULTS: Compared with healthy controls, FM patients had significantly higher levels of Glu (mean +/- SD 8.09 +/- 0.72 arbitrary institutional units versus 6.86 +/- 1.29 arbitrary institutional units; P = 0.009) and combined glutamine and Glu (i.e., Glx) (mean +/- SD 12.38 +/- 0.94 arbitrary institutional units versus 10.59 +/- 1.48 arbitrary institutional units; P = 0.001) within the right posterior insula. No significant differences between groups were detected in any of the other major metabolites within this region (P > 0.05 for all comparisons), and no group differences were detected for any metabolite within the right anterior insula (P > 0.11 for all comparisons). Within the right posterior insula, higher levels of Glu and Glx were associated with lower pressure pain thresholds across both groups for medium pain (for Glu, r = -0.43, P = 0.012; for Glx, r = -0.50, P = 0.003). CONCLUSION: Enhanced glutamatergic neurotransmission resulting from higher concentrations of Glu within the posterior insula may play a role in the pathophysiology of FM and other central pain augmentation syndromes.
OBJECTIVE: Central pain augmentation resulting from enhanced excitatory and/or decreased inhibitory neurotransmission is a proposed mechanism underlying the pathophysiology of functional pain syndromes such as fibromyalgia (FM). Multiple functional magnetic resonance imaging studies implicate the insula as a region of heightened neuronal activity in this condition. Since glutamate (Glu) is a major cortical excitatory neurotransmitter that functions in pain neurotransmission, we undertook this study to test our hypothesis that increased levels of insular Glu would be present in FM patients and that the concentration of this molecule would be correlated with pain report. METHODS: Nineteen FM patients and 14 age- and sex-matched pain-free controls underwent pressure pain testing and a proton magnetic resonance spectroscopy session in which the right anterior insula and right posterior insula were examined at rest. RESULTS: Compared with healthy controls, FM patients had significantly higher levels of Glu (mean +/- SD 8.09 +/- 0.72 arbitrary institutional units versus 6.86 +/- 1.29 arbitrary institutional units; P = 0.009) and combined glutamine and Glu (i.e., Glx) (mean +/- SD 12.38 +/- 0.94 arbitrary institutional units versus 10.59 +/- 1.48 arbitrary institutional units; P = 0.001) within the right posterior insula. No significant differences between groups were detected in any of the other major metabolites within this region (P > 0.05 for all comparisons), and no group differences were detected for any metabolite within the right anterior insula (P > 0.11 for all comparisons). Within the right posterior insula, higher levels of Glu and Glx were associated with lower pressure pain thresholds across both groups for medium pain (for Glu, r = -0.43, P = 0.012; for Glx, r = -0.50, P = 0.003). CONCLUSION: Enhanced glutamatergic neurotransmission resulting from higher concentrations of Glu within the posterior insula may play a role in the pathophysiology of FM and other central pain augmentation syndromes.
Authors: Steven P Cohen; Michael H Verdolin; Audrey S Chang; Connie Kurihara; Bennie J Morlando; Jianren Mao Journal: J Pain Date: 2006-06 Impact factor: 5.820
Authors: Leslie J Crofford; Michael C Rowbotham; Philip J Mease; I Jon Russell; Robert H Dworkin; Ann E Corbin; James P Young; Linda K LaMoreaux; Susan A Martin; Uma Sharma Journal: Arthritis Rheum Date: 2005-04
Authors: Lesley M Arnold; Yili Lu Pritchett; Deborah N D'Souza; Daniel K Kajdasz; Smriti Iyengar; Joachim F Wernicke Journal: J Womens Health (Larchmt) Date: 2007-10 Impact factor: 2.681
Authors: Patricia Cagnoli; Richard E Harris; Dan Frechtling; George Berkis; Richard H Gracley; Courtney C Graft; Suzan E Lowe; Thomas L Chenevert; William J McCune; Stephen Gebarski; Pia C Sundgren Journal: Acad Radiol Date: 2013-10 Impact factor: 3.173
Authors: Chad M Brummett; Jenna Goesling; Alex Tsodikov; Taha S Meraj; Ronald A Wasserman; Daniel J Clauw; Afton L Hassett Journal: Arthritis Rheum Date: 2013-12
Authors: P Feraco; A Bacci; Fab Pedrabissi; L Passamonti; G Zampogna; Fed Pedrabissi; N Malavolta; M Leonardi Journal: AJNR Am J Neuroradiol Date: 2011-07-28 Impact factor: 3.825
Authors: Li Rebekah Feng; Brian S Wolff; Nada Lukkahatai; Alexandra Espina; Leorey N Saligan Journal: Cancer Nurs Date: 2017 May/Jun Impact factor: 2.592
Authors: Steven E Harte; Mainak Mitra; Eric A Ichesco; Megan E Halvorson; Daniel J Clauw; Albert J Shih; Grant H Kruger Journal: Med Biol Eng Comput Date: 2013-02-05 Impact factor: 2.602
Authors: Nicolas Fayed; Javier Garcia-Campayo; Rosa Magallón; Helena Andrés-Bergareche; Juan V Luciano; Eva Andres; Julián Beltrán Journal: Arthritis Res Ther Date: 2010-07-07 Impact factor: 5.156